§ Sources
Sources.
Sources are listed by the chapter in which they are first used. Status and prices are as of the month this book is current to.
- Opening — FDA, Philadelphia District. Form FDA 483, Inspectional Observations: Philips Respironics, Inc., Murrysville, PA (FEI 2518422). Issued 9 November 2021. 28 pages, with the explanatory reverse page. https://fda.gov/media/154244/download (FDA's foam-testing page links the form as https://www.fda.gov/media/154099/download?attachment; redactions are FDA's)
- Opening — FDA. Recalled Philips Ventilators, BiPAP Machines, and CPAP Machines. Web page, content current as of 20 November 2024. https://www.fda.gov/medical-devices/respiratory-devices/recalled-philips-ventilators-bipap-machines-and-cpap-machines
- Opening — FDA. Problems Reported with Recalled Philips Ventilators, BiPAP Machines, and CPAP Machines. Web page, content current as of 31 January 2024. https://www.fda.gov/medical-devices/recalled-philips-ventilators-bipap-machines-and-cpap-machines/problems-reported-recalled-philips-ventilators-bipap-machines-and-cpap-machines
- Ch. 1 — SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks). Opinion on the safety of medical devices containing DEHP-plasticized PVC or other plasticizers on neonates and other groups possibly at risk (2015 update). Final opinion. 25 June 2015. https://health.ec.europa.eu/document/download/d17de743-1077-4654-81a7-b4148667f20c_en?filename=scenihr_o_047.pdf (summary: https://health.ec.europa.eu/publications/safety-medical-devices-containing-dehp-plasticized-pvc-or-other-plasticizers-neonates-and-other_da)
- Ch. 1 — Williams D.F. Specifications for innovative, enabling biomaterials based on the principles of biocompatibility mechanisms. Front Bioeng Biotechnol 7, 255 (2019). doi:10.3389/fbioe.2019.00255 (review; cites the definition from Williams D.F., Definitions in Biomaterials, Proceedings of a Consensus Conference of the European Society for Biomaterials, Chester, Elsevier, which this citation dates 1986; author also lists Strait Access Technologies, a company, and declares no commercial or financial relationships)
- Ch. 1 — ISO. ISO 10993-1:2025, Biological evaluation of medical devices — Part 1: Requirements and general principles for the evaluation of biological safety within a risk management process. Sixth edition, November 2025. Catalogue page: https://www.iso.org/standard/10993-1 ; foreword, introduction and contents on the ANSI Webstore, a reseller: https://webstore.ansi.org/preview-pages/ISO/preview_ISO+10993-1-2025.pdf
- Ch. 1 — FDA. Use of International Standard ISO 10993-1, "Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process". Guidance for Industry and FDA Staff. Final. 8 September 2023. https://www.fda.gov/media/142959/download
- Ch. 1 — FDA. Basics of Biocompatibility: Information Needed for Assessment by the FDA. Web page, content current as of 7 September 2023. https://www.fda.gov/medical-devices/biocompatibility-assessment-resource-center/basics-biocompatibility-information-needed-assessment-fda
- Ch. 1 — FDA. Applying Human Factors and Usability Engineering to Medical Devices. Guidance, Sections 3 and 7 (reproduces the ISO 14971:2019 terms hazard, hazardous situation and harm; reports ISO 14971's risk control options in order of preference and residual risk). 3 August 2026. https://www.fda.gov/media/80481/download
- Ch. 1 — Health Canada. Risk classification guide for medical device establishment inspections (GUI-0079), version 4 (reproduces the ISO 14971:2019 definition of risk). Issued 21 November 2025; replaces version 3 of 9 December 2022. https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/medical-devices/guidance-risk-classification-medical-device-observations-0079.html
- Ch. 1 — FDA. 510(k) Summary K251770, SleepRes PAP System (Sleepres, Inc.). Cleared 15 December 2025. https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251770.pdf (manufacturer's summary)
- Ch. 1 — FDA. 510(k) Summary K242547, AirFit F20 / AirFit F20 NM Mask System (ResMed Pty Ltd). Cleared 19 May 2025. https://www.accessdata.fda.gov/cdrh_docs/pdf24/K242547.pdf (manufacturer's summary)
- Ch. 1 — FDA. 510(k) Summary K251920, JoyMask 20-B and 21-B Full Face Mask (Dcstar, Inc.). Cleared 21 May 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251920.pdf (manufacturer's summary)
- Ch. 1 — FDA. 510(k) Summary K193206, WiZARD 510 Nasal Mask (Apex Medical Corp.). Cleared 29 October 2020. https://www.accessdata.fda.gov/cdrh_docs/pdf19/K193206.pdf (manufacturer's summary)
- Ch. 1 — Element (test laboratory). ISO 18562 white paper. Undated. https://www.element.com/-/media/files/life-sciences/element-life-sciences-iso-18562-white-paper.pdf (secondary, commercial; condensate part of ISO 18562)
- Ch. 1 — Hood A. (FDA CDRH/OPEQ), Kennedy T. (W.L. Gore & Associates), Parker S. (SParker Toxicology Consulting). ISO 10993-17 MDCPSS Webinar Part 1. Slides. Society of Toxicology, Medical Device and Combination Product Specialty Section. 11 January 2024. https://www.toxicology.org/groups/ss/MDCPSS/docs/_mtg-events/ISO-10993-17-MDCPSS-Webinar-Part-1.pdf (secondary, slides citing ISO 10993-17:2023 Annex D; one presenter FDA staff, one a device maker's staff and one a toxicology consultant)
- Ch. 2 — Møkleby M., Øverland B. Long-term use of CPAP in patients with obstructive sleep apnea: a prospective longitudinal cohort study. Sleep Biol Rhythms 20(2), 239–246 (2022). doi:10.1007/s41105-021-00361-6 (prospective cohort, one urban sleep centre in Norway, 163 started, 99 analysed at long-term follow-up; hours from device downloads; funder University of Oslo)
- Ch. 2 — Pépin J.L., Bailly S., Rinder P., et al.; medXcloud Group. CPAP therapy termination rates by OSA phenotype: a French nationwide database analysis. J Clin Med 10(5), 936 (2021). doi:10.3390/jcm10050936 (retrospective claims cohort, 480,000 patients; unrestricted grant from ResMed, medical writing funded by ResMed; three authors ResMed employees)
- Ch. 2 — Ahola L. (Measurlabs). ISO 10993-1:2025 – Key changes at a glance. 6 February 2026. https://measurlabs.com/blog/changes-to-iso-10993-1-standard/ (testing laboratory's note, company)
- Ch. 2 — NAMSA. ISO 10993-1:2025 Updates — Top 10 Biological Evaluation Essentials in the Revision. Undated (after November 2025). https://namsa.com/resources/blog/iso-10993-12025top-10-biological-evaluation-essentials-in-the-update/ (contract research organization's note, company; reproduces the standard's terms)
- Ch. 2 — FDA. 510(k) Summary K160764, AirLife Autofill Humidification Chamber (CareFusion 2200, Inc.). Cleared 25 August 2016. https://www.accessdata.fda.gov/cdrh_docs/pdf16/K160764.pdf (manufacturer's summary)
- Ch. 2 — Barden D., Roberts G.M. (Markes International). Monitoring emissions from respiratory medical devices in accordance with ISO 18562-3. The Application Notebook (LCGC) 30(4), 1 December 2017. https://chromatographyonline.com/view/monitoring-emissions-respiratory-medical-devices-accordance-iso-18562-3 (instrument maker's application note; company staff; the company sells the instruments used)
- Ch. 2 — NAMSA (Smiraldo P., Ruch C.). Understanding the ISO 18562:2024 Standards Update for Medical Devices. Undated. https://namsa.com/resources/blog/understanding-the-iso-185622024-standards-update-for-medical-devices/ (contract research organization's note, company)
- Ch. 2 — Labcorp. Navigating the revision of ISO 10993-1. 2 September 2025. https://www.labcorp.com/education-events/articles/navigating-revision-iso-10993-1-biological-evaluation-medical-devices (contract research organization's note, written before the 2025 edition was published)
- Ch. 2 — FDA CDRH (Malone M., Li S., Ghosh C., Bancos S.). Biocompatibility Town Hall #1: Risk Assessment Approaches for Addressing Biocompatibility Endpoints. Slides. 9 September 2026. https://www.fda.gov/media/194891/download (regulator's presentation, not guidance)
- Ch. 2 — Chiara A. (Complife). Biocompatibility and biological safety of medical devices: what's new in ISO Standards 2025–2026. 25 May 2026. https://www.complifegroup.com/2026/05/25/biocompatibility-and-biological-safety-of-medical-devices-whats-new-in-iso-standards-2025-2026/ (testing laboratory's note, company)
- Ch. 2 — Centers for Medicare & Medicaid Services, Medicare Learning Network. Positive Airway Pressure (PAP) Devices: Complying with Documentation & Coverage Requirements. ICN 905064. October 2016. https://www.cms.gov/files/document/papdoccvgfactsheeticn905064textonlypdf (coverage fact sheet)
- Ch. 2 — Bollen L.S., Svendsen O. Regulatory guidelines for biocompatibility safety testing. MD&DI, May 1997. https://www.mddionline.com/regulatory-quality/regulatory-guidelines-for-biocompatibility-safety-testing (trade-press review of the standard as it then stood)
- Ch. 2 — CGS Medicare (DME MAC). Physicians! Are You Ordering PAP Devices and Related Accessories for your Patients? Undated; cites LCD L33718. https://cgsmedicare.com/pdf/dme_ordering/pap_devices.pdf (a Medicare contractor's statement of the adherence rule)
- Ch. 3 — Hahladakis J.N., Velis C.A., Weber R., Iacovidou E., Purnell P. An overview of chemical additives present in plastics: migration, release, fate and environmental impact during their use, disposal and recycling. J Hazard Mater 344, 179–199 (2018). doi:10.1016/j.jhazmat.2017.10.014
- Ch. 3 — SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks). The safety of the use of bisphenol A in medical devices. Final opinion. Adopted 18 February 2015. https://health.ec.europa.eu/document/download/bb2245e3-8c06-468b-931e-ca4aa50a4790_en?filename=scenihr_o_040.pdf
- Ch. 3 — Ruberto M.A. Polymers and additives used in fabrication of disposable bioprocess equipment. BioProcess International, 1 April 2010. https://bioprocessintl.com/monoclonal-antibodies/polymers-and-additives-used-in-fabrication-of-disposable-bioprocess-equipment (trade-journal review; the author co-wrote the Ciba poster below)
- Ch. 3 — Grzęda D., Węgrzyk G., Nowak A., Komorowska G., Szczepkowski L., Ryszkowska J. Effect of different amine catalysts on the thermomechanical and cytotoxic properties of 'visco'-type polyurethane foam for biomedical applications. Materials 16(4), 1527 (2023). doi:10.3390/ma16041527 (funded by Warsaw University of Technology; one author from Fampur Adam Przekurat; the authors declare no conflict of interest)
- Ch. 3 — Swain E. New medical grades of PVC hit the market. Medical Device & Diagnostic Industry, 1 July 2004. https://www.mddionline.com/medical-device-markets/new-medical-grades-of-pvc-hit-the-market (trade press reporting company statements)
- Ch. 3 — van Beusichem B., Ruberto M.A. (Ciba Specialty Chemicals). Polymer additives. Poster, Product Quality Research Institute. Undated. https://pqri.org/wp-content/uploads/2015/08/pdf/Polymer_Additives_PQRI_Poster.pdf (manufacturer: the authors' company made the antioxidants named)
- Ch. 3 — ASTM International. ASTM F2038-00 (Reapproved 2011). Standard guide for silicone elastomers, gels, and foams used in medical applications, Part I: formulations and uncured materials. Reapproved 1 December 2011; marked superseded or withdrawn on the extract hosted by iTeh Standards: https://cdn.standards.iteh.ai/samples/79010/5c49d8bc1a764c71a0999abc02738cd8/ASTM-F2038-00-2011-.pdf
- Ch. 3 — MilliporeSigma (Merck KGaA). Reducing the need for animal testing. Technical article. 10 July 2024. https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/pharmaceutical-and-biopharmaceutical-manufacturing/final-fill-strategies/reducing-need-for-animal-testing (manufacturer)
- Ch. 3 — MD+DI. The importance of USP Class VI testing. Undated. https://www.mddionline.com/testing/the-importance-of-usp-class-vi-testing (trade press; author not named)
- Ch. 3 — USP. <88> Biological Reactivity Tests, In Vivo. USP–NF (2024). https://doi.usp.org/USPNF/USPNF_M98834_02_01.html (USP–NF online page; it carries no version or official date)
- Ch. 3 — Gerlach M. Is your supply chain ready for the end of Class VI? Bioprocess Online, 21 October 2026. https://www.bioprocessonline.com/doc/is-your-supply-chain-ready-for-the-end-of-class-vi-0001 (trade press guest column; secondary)
- Ch. 3 — FDA. Master Files. Web page. Content current as of 6 December 2023. https://www.fda.gov/medical-devices/premarket-approval-pma/master-files
- Ch. 3 — Resvent Medical Technology Co., Ltd. 510(k) Summary K253044, RXiBreeze PAP System. Cleared by FDA 23 July 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf25/K253044.pdf (manufacturer's summary; names no component materials)
- Ch. 3 — BMC Medical Co., Ltd. 510(k) Summary K211155, Auto CPAP System. FDA letter 9 March 2022. https://www.accessdata.fda.gov/cdrh_docs/pdf21/K211155.pdf (manufacturer's summary; names no component materials)
- Ch. 4 — Jaeger R.J., Rubin R.J. Plasticizers from plastic devices: extraction, metabolism, and accumulation by biological systems. Science 170(3956), 460–462 (1970). doi:10.1126/science.170.3956.460 (OpenAlex record W2014016832)
- Ch. 4 — Jaeger R.J., Rubin R.J. Migration of a phthalate ester plasticizer from polyvinyl chloride blood bags into stored human blood and its localization in human tissues. N Engl J Med 287(22), 1114–1118 (1972). doi:10.1056/NEJM197211302872203 (OpenAlex record W2015697520)
- Ch. 4 — Duda J.L. Molecular diffusion in polymeric systems. Pure Appl Chem 57(11), 1681–1690 (1985). © IUPAC. https://joomla.iupac.org/publications/pac/1985/pdf/5711x1681.pdf
- Ch. 4 — European Commission, Joint Research Centre; Simoneau C. (ed.), Brandsch R., Brands B., Franz R., Klatt M., Milana M.R., Piringer O., Schaefer A., Trier X., Vitrac O. Applicability of generally recognised diffusion models for the estimation of specific migration in support of EU Directive 2002/72/EC. EUR 24514 EN. 2010. https://publications.jrc.ec.europa.eu/repository/bitstream/JRC59476/reqno_jrc59476_mathmod_v10_cs_2010_09_24_final.pdf%5B1%5D.pdf (the upper-bound migration model and its caveat)
- Ch. 4 — Saylor D.M. (FDA CDRH, Office of Science and Engineering Laboratories). Slides on physics-based estimates of patient exposure to device leachables (FDA staff presentation, not guidance; undated). Society of Toxicology, Medical Device and Combination Product Specialty Section. https://www.toxicology.org/groups/ss/MDCPSS/docs/_mtg-events/SOT_MDCPSS_David_Saylor.pdf
- Ch. 4 — FDA. Intravascular Administration Sets: Premarket Notification Submissions [510(k)]. Guidance for Industry and FDA Staff. 11 July 2008. https://www.fda.gov/media/71046/download
- Ch. 4 — FDA. Recognized Consensus Standards, record 45635: ISO 80601-2-79 (second edition 2024-08), whose relevant standards include ISO 18562-1 to -4, second edition 2024-03 (risk management, particulate matter, volatile organic compounds, leachables in condensate). Entered 23 December 2024. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.cfm?standard__identification_no=45635
- Ch. 4 — ISO. ISO 10993-18:2020, Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process. 2nd edition, January 2020 (amended 2022). Foreword to clause 5.1, with terms 3.1 to 3.40, hosted by iTeh Standards: https://cdn.standards.iteh.ai/samples/64750/9b92d06fc094405790ae06701269b7d4/ISO-10993-18-2020.pdf
- Ch. 4 — ICH. Q3E Guideline for Extractables and Leachables. Draft, Step 2, endorsed 1 August 2025 (under public consultation). https://www.fda.gov/media/189890/download
- Ch. 4 — SCHEER (Scientific Committee on Health, Environmental and Emerging Risks). Update of the guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties. Final, adopted 14 June 2024. https://health.ec.europa.eu/document/download/1780f59c-c3a4-4eca-8366-ca9e48934889_en?filename=scheer_o_064.pdf
- Ch. 4 — FDA. Chemical Analysis for Biocompatibility Assessment of Medical Devices. Draft guidance, not for implementation. September 2024 (FDA's guidance page is current as of 19 September 2024). Docket FDA-2024-D-4165. https://www.fda.gov/media/181952/download
- Ch. 4 — FDA. Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coatings – Labeling Considerations. Guidance for Industry and FDA Staff. 10 October 2019. https://www.fda.gov/media/113951/download
- Ch. 5 — Hollingsworth B.L., Ledbury K.J., Stokoe A.L. The accelerated ageing of some commercial polyurethane rubbers. Explosives Research and Development Establishment, Waltham Abbey, Technical Memorandum 211/66. 18 January 1967. DTIC AD0661499. https://apps.dtic.mil/sti/pdfs/AD0661499.pdf (UK Ministry of Technology establishment; 1967 grades)
- Ch. 5 — Pegoretti A., Penati A., Kolarik J. Effect of hydrolysis on molar mass and thermal properties of poly(ester urethanes). J Therm Anal 41, 1441–1452 (1994). Author-hosted copy: https://pegoretti.dii.unitn.it/resources/Untitled-Folder/Papers/6-Pegoretti-Effect-of-hydrolysis-on-molar-mass-and-thermal-properties-of-poly-ester-urethanes_JTA-1994.pdf
- Ch. 5 — Brannigan R.P., Dove A.P. Synthesis, properties and biomedical applications of hydrolytically degradable materials based on aliphatic polyesters and polycarbonates. Biomater Sci (2017; first published 14 November 2016). doi:10.1039/C6BM00584E. https://pubs.rsc.org/en/content/articlehtml/2017/bm/c6bm00584e (review)
- Ch. 5 — Miri Z., Farè S., Ma Q., Haugen H.J. Updates on polyurethane and its multifunctional applications in biomedical engineering. Prog Biomed Eng 5, 042001 (2023). doi:10.1088/2516-1091/acef84 (review; CC BY 4.0; no conflict of interest reported)
- Ch. 5 — Hong K.Z., Qin C., Woo L. Explaining ductility loss in steam-sterilized polycarbonate. Medical Plastics and Biomaterials, May 1996 (MD+DI online). https://www.mddionline.com/sterilization/explaining-ductility-loss-steam-sterilized-polycarbonate (manufacturer: all authors Baxter Healthcare staff; trade magazine)
- Ch. 5 — Schubert M.A., Wiggins M.J., Schaefer M.P., Hiltner A., Anderson J.M. Oxidative biodegradation mechanisms of biaxially strained poly(etherurethane urea) elastomers. J Biomed Mater Res 29(3), 337–347 (1995). doi:10.1002/jbm.820290309
- Ch. 5 — Zaikov G., Rakovsky S., Anachkov M. Ozone and its reactions with diene rubbers. Chem Chem Technol 6(3), 307 (2012). doi:10.23939/chcht06.03.307 (review with the authors' data)
- Ch. 5 — Bergstrom E.W. The long-term effectiveness of chemical vs. polymeric antiozonants in rubber. Rock Island Arsenal, Rodman Laboratory, Report R-TR-76-027. February 1976. DTIC ADA029732. https://apps.dtic.mil/sti/pdfs/ADA029732.pdf (US Army laboratory report)
- Ch. 5 — FDA. Do you need a device that claims to clean a CPAP machine? Consumer update. 30 August 2024. https://www.fda.gov/consumers/consumer-updates/do-you-need-device-claims-clean-cpap-machine
- Ch. 5 — Taourit S., Le Gac P.Y., Fayolle B. Relationship between network structure and ultimate properties in polyurethane during a chain scission process. Polym Degrad Stab 201, 109971 (2022). doi:10.1016/j.polymdegradstab.2022.109971 (funded by the Dutch Polymer Institute, project 828)
- Ch. 5 — Hemmerich K.J. General aging theory and simplified protocol for accelerated aging of medical devices. Medical Device & Diagnostic Industry, 1 July 1998. https://www.mddionline.com/design-engineering/general-aging-theory-and-simplified-protocol-for-accelerated-aging-of-medical-devices (trade journal; the author managed a gamma-irradiation facility for Isomedix, a sterilization company)
- Ch. 5 — Janting J., Theander J.G., Egesborg H. On thermal acceleration of medical device polymer aging. IEEE Trans Device Mater Reliab 19(2), 313–321 (2019). doi:10.1109/TDMR.2019.2907080 (company authors: Theander, ConvaTec; Egesborg, MedDevCon)
- Ch. 5 — FDA. Recognized Consensus Standards: ASTM F1980-21, Standard guide for accelerated aging of sterile barrier systems for medical devices. Recognition 14-575, entered 20 February 2023. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/detail.cfm?standard__identification_no=44089
- Ch. 5 — ASTM International. F1980-16, Standard guide for accelerated aging of sterile barrier systems for medical devices (historical edition). Catalogue page. https://store.astm.org/f1980-16.html
- Ch. 5 — Mahomed A., Hukins D.W.L., Kukureka S.N. Effect of accelerated aging on the viscoelastic properties of a medical grade silicone. Biomed Mater Eng 25, 415 (2015). doi:10.3233/BME-151538
- Ch. 5 — Philips Respironics. Update on PE-PUR testing results and conclusions available to date. April 2023, updated 16 May 2023. https://www.philips.ca/c-dam/b2bhc/master/landing-pages/src/update/documents/philips-respironics-update-on-pe-pur-testing-results-and-conclusions-available-to-date-20230516.pdf (manufacturer)
- Ch. 5 — University of Wuppertal, Chemistry Didactics, in cooperation with WACKER. Influence of ozone on silicone rubber and other types of rubber. Experiment page, undated. https://chemiedidaktik.uni-wuppertal.de/fileadmin/Chemie/chemiedidaktik/disido/en/exp/prop06.htm
- Ch. 6 — Alotaibi M., Aldhafeeri T., Barry C. The impact of reprocessing with a quad screw extruder on the degradation of polypropylene. Polymers 14(13), 2661 (2022). doi:10.3390/polym14132661 (no external funding stated)
- Ch. 6 — Allen N.S., Edge M., Liauw C.M., Hoang E., Fontan E. Role of phenol and phosphite antioxidant combinations in the thermal stabilisation of metallocene LLDPE: optimisation and performance and influence of metal stearates on multiple extrusions. Polym Degrad Stab 152, 208–217 (2018). doi:10.1016/j.polymdegradstab.2018.04.032 (accepted manuscript: https://e-space.mmu.ac.uk/620710/; partly funded by Repsol and Chemtura, now Addivant; two authors company staff: Hoang, Element Ltd., and Fontan, Repsol)
- Ch. 6 — Diamantidou D., Tsochatzis E., Kalogiannis S., Lopes J.A., Theodoridis G., Gika H. Analysis of migrant cyclic PET oligomers in olive oil and food simulants using UHPLC-qTOF-MS. Foods 12(14), 2739 (2023). doi:10.3390/foods12142739 (funded by Greece and the EU; oligomer formation in the melt is cited by the paper, not measured in it)
- Ch. 6 — FDA. Component and Device Documentation Examples: Test Articles or Previously Marketed Devices. Biocompatibility Assessment Resource Center (web resource, not a guidance document). Content current as of 7 September 2023. https://www.fda.gov/medical-devices/biocompatibility-assessment-resource-center/component-and-device-documentation-examples-test-articles-or-previously-marketed-devices
- Ch. 6 — Thompson-Torgerson C.S., Champion H.C., Santhanam L., Harris Z.L., Shoukas A.A. Cyclohexanone contamination from extracorporeal circuits impairs cardiovascular function. Am J Physiol Heart Circ Physiol 296(6), H1926–H1932 (2009). doi:10.1152/ajpheart.00184.2009 (OpenAlex record W2108721574; funded by NHLBI; no company authors)
- Ch. 6 — Everett A.D., Buckley J.P., Ellis G.S., et al. Association of neurodevelopmental outcomes with environmental exposure to cyclohexanone during neonatal congenital cardiac operations: a secondary analysis of a randomized clinical trial. JAMA Netw Open 3(5), e204070 (2020). doi:10.1001/jamanetworkopen.2020.4070 (funded by NHLBI, NICHD, the Children's Heart Foundation and Johns Hopkins University; no company authors)
- Ch. 6 — FDA CDRH, Office of Product Evaluation and Quality. Biocompatibility Town Hall #2: Extractions for Conducting Chemical Analysis for Biocompatibility Assessment. Slides (FDA staff presentation, not guidance), 23 September 2026, on the draft guidance of September 2024, which is not for implementation. Docket FDA-2024-D-4165. https://www.fda.gov/media/195196/download (slide 16 quotes ISO 10993-12, edition not stated)
- Ch. 6 — FDA. Deciding When to Submit a 510(k) for a Change to an Existing Device. Guidance for Industry and FDA Staff. 25 October 2017. https://www.fda.gov/media/99812/download
- Ch. 7 — Cingolani A., Casalini T., Caimi S., Klaue A., Sponchioni M., Rossi F., Perale G. A methodologic approach for the selection of bio-resorbable polymers in the development of medical devices: the case of poly(l-lactide-co-ε-caprolactone). Polymers 10(8), 851 (2018). doi:10.3390/polym10080851 (no external funding stated; one affiliation is Industrie Biomediche Insubri SA, a device company)
- Ch. 7 — STERIS Applied Sterilization Technologies. Overview of Ethylene Oxide Residuals (Tech Tip). Undated web page, accessed 13 November 2026. https://www.steris-ast.com/techtip/overview-ethylene-oxide-residuals/ (a sterilization contractor; its limit table describes the withdrawn ISO 10993-7:2008)
- Ch. 7 — ISO. ISO 10993-7:2026, Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals. 3rd edition, 20 April 2026 (replaces ISO 10993-7:2008, Cor 1:2009 and Amd 1:2019, withdrawn). Table 1; clauses 4.1 and 4.3.1, hosted by iTeh Standards: https://cdn.standards.iteh.ai/samples/iso/iso-10993-7-2026/91e3fd70f1a4489f86fa78bb9d7d5fda/iso-10993-7-2026.pdf. Catalogue page: https://committee.iso.org/standard/84824.html
- Ch. 7 — NAMSA. ISO 10993-7 Primer: Testing for Ethylene Oxide Sterilization Residuals. Undated web page, accessed 13 November 2026. https://namsa.com/resources/blog/iso-10993-7-ethylene-oxide-sterilization-residuals/ (a contract research laboratory; describes the withdrawn 2008 edition)
- Ch. 7 — DQS Medizinprodukte (Notified Body 0297). ISO 10993-7:2026: What the new revision means for ethylene oxide sterilization residuals. 3 June 2026. https://www.dqsglobal.com/en/explore/blog/iso-10993-7-2026-ethylene-oxide-sterilization-residuals (notified body staff; no numeric limits given)
- Ch. 7 — Eurofins Medical Device Services. Regulatory must reads: EO sterilization in transition – regulatory shifts and industry impact. 12 May 2026, updated 18 June 2026. https://www.eurofins.com/en-us/biopharma-services/medical-device-services/news/regulatory-must-reads-eo-sterilization-in-transition-regulatory-shifts-industry-impact/ (testing laboratory staff; no numeric limits given)
- Ch. 7 — European Commission. Commission Implementing Decision (EU) 2026/2479 of 9 November 2026 amending Implementing Decision (EU) 2021/1182 as regards harmonised standards for sterilization of health care products, clinical investigation, biological evaluation of medical devices and other items. OJ L, 10 November 2026 (in force on publication; adds EN ISO 10993-6:2026 and EN ISO 10993-7:2026). https://eur-lex.europa.eu/eli/dec_impl/2026/2479/oj/eng/pdf
- Ch. 7 — FDA. Recognized Consensus Standards: Medical Devices, search results for reference number 10993 (ISO 10993-7:2008 with TC1:2009 and AMD1:2019, recognition 2-275; ISO 10993-6:2016, recognition 2-247; no 2026 edition of parts 6 or 7 recognized). Accessed 13 November 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/results.cfm?referencenumber=10993
- Ch. 7 — Sterigenics U.S., LLC. Material Consideration: Radiation Processing. AC105.0004-1(4/18). September 2018. https://sterigenics.com/wp-content/uploads/2018/09/Material-Considerations-Irradiation-Processing_WEB-v3.pdf (company document of a contract sterilizer; ratings, not thresholds)
- Ch. 7 — Naikwadi A.T., Sharma B.K., Bhatt K.D., Mahanwar P.A. Gamma radiation processed polymeric materials for high performance applications: a review. Front Chem 10, 837111 (2022). doi:10.3389/fchem.2022.837111 (funding not stated)
- Ch. 7 — Jahan M.S., Thomas D.E., Trieu H.H., Haggard W.O., Conta R.L., Parr J.E. Investigation of free radicals in shelf-aged polyethylene tibial components. Transactions of the Society for Biomaterials 1, 298 (1996). https://digitalcommons.memphis.edu/facpubs/6708 (meeting abstract)
- Ch. 7 — Lu S., Orr J., Buchanan F. The influence of inert packaging on the shelf ageing of gamma-irradiation sterilised ultra-high molecular weight polyethylene. Biomaterials 24(1), 139–145 (2003). doi:10.1016/S0142-9612(02)00271-5
- Ch. 7 — Kucharska-Jastrząbek A., Chmal-Fudali E., Rudnicka D., Kosińska B. Effect of sterilization on bone implants based on biodegradable polylactide and hydroxyapatite. Materials 16(15), 5389 (2023). doi:10.3390/ma16155389 (funded by Poland's National Centre for Research and Development, grant POIR.01.01.01-00-0646/19; no company authors)
- Ch. 7 — ASTM International. ASTM F1980-21 Standard Guide for Accelerated Aging of Sterile Barrier Systems and Medical Devices. Active standard. Catalogue page, last updated 21 December 2021, accessed 13 November 2026. https://store.astm.org/f1980-21.html
- Ch. 7 — FDA. Continuous Positive Airway Pressure (CPAP) Machine Cleaning. Consumer Update. Posted 30 August 2024, content current as of 26 August 2024. https://www.fda.gov/consumers/consumer-updates/continuous-positive-airway-pressure-cpap-machine-cleaning
- Ch. 7 — FDA. Voluntary Recall of SoClean Equipment Intended for Use with CPAP Devices and Accessories: FDA Safety Communication. 21 November 2023, updated August 2024 (content current as of 26 August 2024). https://www.fda.gov/medical-devices/safety-communications/voluntary-recall-soclean-equipment-intended-use-cpap-devices-and-accessories-fda-safety
- Ch. 7 — FDA. De Novo classification DEN210037, SoClean 3+ Bacterial Reduction Device (respiratory accessory microbial reduction device, 21 CFR 880.6993, Class II). Granted 12 August 2024. Database record https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN210037 and decision summary https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN210037.pdf (applies the 0.05 ppm ozone level of 21 CFR 801.415; test data are the sponsor's)
- Ch. 7 — FDA. 510(k) Premarket Notification K243815, SoClean 3+. Cleared 10 October 2025. https://www.accessdata.fda.gov/cdrh_docs/pdf24/K243815.pdf (summary text and test data are the sponsor's, SoClean, Inc.)
- Ch. 7 — FDA. 518(a) Notification Order Re: Philips Respironics Recall. 10 March 2022. https://www.fda.gov/media/156811/download?attachment
- Ch. 8 — Kudzin M.H., Sikora M., Mrozińska Z., Chruściel J.J. Polymeric fibrous materials for procoagulant and anticoagulant applications: a review of molecular blood–material mechanisms and strategies. Materials 19(3), 539 (2026). doi:10.3390/ma19030539 (review, open access)
- Ch. 8 — Barberi J., Spriano S. Titanium and protein adsorption: an overview of mechanisms and effects of surface features. Materials 14(7), 1590 (2021). doi:10.3390/ma14071590 (review, open access; written about titanium)
- Ch. 8 — Vroman L., Adams A.L., Fischer G.C., Munoz P.C. Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. Blood 55(1), 156–159 (1980). PMID 7350935. Scilit record: https://scilit.com/publications/58740f8f73d2e77302ec4396b82145ec
- Ch. 8 — Sheikh Z., Brooks P.J., Barzilay O., Fine N., Glogauer M. Macrophages, foreign body giant cells and their response to implantable biomaterials. Materials 8(9), 5671–5701 (2015). doi:10.3390/ma8095269 (review)
- Ch. 9 — Wallin R.F., Upman P.J. A practical guide to ISO 10993-6: implant effects. Medical Device & Diagnostic Industry (MD&DI), 1 August 1998. https://www.mddionline.com/implants/a-practical-guide-to-iso-10993-6-implant-effects (trade press; authors at NAMSA, a contract testing laboratory; describes the edition of the 1990s, since superseded)
- Ch. 9 — International Commission on Radiological Protection. Human respiratory tract model for radiological protection. ICRP Publication 66. Annals of the ICRP 24(1–3) (1994). PMID 7726471 (EPA HERO record: https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6988)
- Ch. 9 — Gregoratto D. Main characteristics of the Human Respiratory Tract Model (HRTM) used in the OIR and EIR series. Slides, ICRP Task Group 95 webinar, Internal Dose Coefficients for Workers and Members of the Public, 6 December 2023. https://icrp.org/admin/2023-12-06_TG95-Webinar_D-Gregoratto.pdf (slides hosted by ICRP; the regions of the respiratory tract model and its revision in ICRP Publication 130, 2015)
- Ch. 9 — Bair W.J. The revised International Commission on Radiological Protection (ICRP) dosimetric model for the human respiratory tract: an overview. Pacific Northwest Laboratory, PNL-SA-18756 (about 1991). https://www.osti.gov/servlets/purl/5011272 (national laboratory report for the ICRP task group; funded by the US Department of Energy)
- Ch. 9 — Brown J.S., Gordon T., Price O., Asgharian B. Thoracic and respirable particle definitions for human health risk assessment. Particle and Fibre Toxicology 10, 12 (2013). doi:10.1186/1743-8977-10-12 (modeling study; first author at the US EPA; two authors at Applied Research Associates, Inc., a company; Gordon funded in part by an EPA faculty appointment; no competing interests declared)
- Ch. 9 — Mintis D.G., Varsou D.D., Kolokathis P.D., et al. LungDepo: modelling the regional particle deposition in the human lung via the Enalos Cloud platform. Environmental Science: Nano (2025). doi:10.1039/d5en00299k (reproduction of the ICRP model through simplified equations; authors at NovaMechanics Ltd., the platform's developer; funded by EU Horizon 2020 grants; no conflicts declared)
- Ch. 9 — FDA. Recognized Consensus Standards: Medical Devices. ISO 18562-2 Second edition 2024-03, recognition number 1-174, entered 29 May 2024. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.cfm?standard__identification_no=45209 (accessed 13 November 2026)
- Ch. 9 — ISO. ISO 10993-6:2026 Biological evaluation of medical devices — Part 6: Tests for local effects after implantation. Edition 4, April 2026. https://www.iso.org/standard/83976.html (catalogue page)
- Ch. 9 — ANSI. ISO 10993-6:2026 – Implantation effects testing. ANSI Blog, undated. https://blog.ansi.org/ansi/iso-10993-6-2026-implantation-effects-testing/ (secondary; ANSI sells the standard)
- Ch. 9 — FDA. Recognized Consensus Standards: Medical Devices, results for ISO 10993 (ISO 10993-6 Third edition 2016-12-01, recognition number 2-247, entered 21 August 2017; no 2026 edition listed). Page last updated 28 September 2026; accessed 13 November 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/results.cfm
- Ch. 10 — Wang J., Jiang X., Liu X., Pan P. Molecular mechanisms of blood–membrane interactions in hemodialysis: advances in anti-inflammatory surface modifications. Membranes 16(10), 332 (2026). doi:10.3390/membranes16100332 (open access; no company affiliations)
- Ch. 10 — Malinauskas R., Liu C., Skoog S., Lu Q. (FDA, Center for Devices and Radiological Health, Office of Science and Engineering Laboratories). Effect of test parameters on material-mediated hemolysis using the ASTM F756-17 standard test method. Poster, undated (results as mean ± SD of triplicates). https://www.fda.gov/media/168742/download
- Ch. 10 — Nelson Laboratories, LLC (Salt Lake City). ASTM hemolysis test report, test article TM7APO (a thermoplastic elastomer compound), study approved 15 November 2019; sponsor Nelson Labs NV (Leuven). Manufacturer document: published by the material's maker, KRAIBURG TPE, in its product database. The report defines the haemolytic index as the hemoglobin released over the hemoglobin present in the diluted blood, corrected for the PBS blank. https://pdb.kraiburg-tpe.com/assets/tpepdb2/imported_documents/COMPOUND_20231130094911_TM7APO_ISO10993-4_TM7APO_.pdf
- Ch. 10 — iTeh Standards (a standards seller). ISO 10993-4:2017/Amd 1, Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood — Amendment 1. Catalogue page with a summary of the amendment (secondary). https://standards.iteh.ai/catalog/standards/iso/4e679ad5-1bc3-44dc-b553-cbee179a50c9/iso-10993-4-2017-amd-1 (accessed 13 November 2026). The page dates its texts 20 November and 7 December 2024 and still shows the amendment at stage 60.00, under publication; that status is out of date, since the amendment was published in January 2025, with a corrected version in April 2025 (next entry). The move of devices that collect, store or give blood to the direct-contact list, the additions to the indirect-contact list and the six test categories rest on this summary.
- Ch. 10 — ISO. ISO 10993-4:2017/Amd 1:2025 Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood — Amendment 1. Published January 2025; corrected version April 2025. Prepared by ISO/TC 194 in collaboration with CEN/TC 206. Cover and foreword hosted by iTeh Standards: https://cdn.standards.iteh.ai/samples/86862/0153fa66d8f24debb0d6a737ef2c4a3f/ISO-10993-4-2017-Amd-1-2025.pdf
- Ch. 10 — Eurofins Medical Device Testing. Insights into in-vitro hemocompatibility testing according to ISO 10993-4. Undated (a testing service provider's own document). https://cdnmediaassets.eurofins.com/eurofins-corporate/media/hmsh3jhi/9438_hemocompatibility_web-ready.pdf
- Ch. 10 — Weber M., Steinle H., Golombek S., Hann L., Schlensak C., Wendel H.P., Avci-Adali M. Blood-contacting biomaterials: in vitro evaluation of the hemocompatibility. Front Bioeng Biotechnol 6, 99 (2018). doi:10.3389/fbioe.2018.00099
- Ch. 11 — ISO. ISO 10993-23:2021 Biological evaluation of medical devices — Part 23: Tests for irritation. Edition 1, published 20 January 2021; confirmed at systematic review on 8 June 2026; amended by ISO 10993-23:2021/Amd 1:2025 (reconstructed human epidermis models). ISO catalogue page: https://committee.iso.org/standard/74151.html
- Ch. 11 — OECD. The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins. Part 1: Scientific evidence. Series on Testing and Assessment No. 168, ENV/JM/MONO(2012)10/PART1. 4 May 2012. https://one.oecd.org/document/ENV/JM/MONO(2012)10/PART1/en/pdf
- Ch. 11 — ECHA. Prolonged contact with the skin – definition building for nickel. 2 April 2014 (a proposal prepared at the European Commission's request, not binding; quotes the limits of REACH Annex XVII entry 27 as then in force). https://echa.europa.eu/documents/10162/13641/nickel_restriction_prolonged_contact_skin_en.pdf/b6f35357-da40-4a04-8085-fe42f6f543ab
- Ch. 11 — Ahlström M.G., Thyssen J.P., Wennervaldt M., Menné T., Johansen J.D. Nickel allergy and allergic contact dermatitis: a clinical review of immunology, epidemiology, exposure, and treatment. Contact Dermatitis 81(4), 227–241 (2019). doi:10.1111/cod.13327 (BVS/MEDLINE record: https://pesquisa.bvsalud.org/bvsms/resource/pt/mdl-31140194)
- Ch. 11 — Ulriksdotter J., Sukakul T., Bruze M., Mowitz M., Ofenloch R., Svedman C. Contact allergy to allergens in the Swedish baseline series overrepresented in diabetes patients with skin reactions to medical devices: a retrospective study from southern Sweden. Acta Derm Venereol 104, adv19676 (2024). doi:10.2340/actadv.v104.19676 (open access; funded by the Gorthon Foundation, Hudfonden, Svenska Diabetesstiftelsen and the Asthma and Allergy Association Research Fund; no company authors; one author on a fragrance-safety expert panel and one in a study for IFRA, as declared)
- Ch. 11 — OECD. Test Guideline No. 406: Skin Sensitisation. Adopted 17 July 1992. Copy held by NIEHS/ICCVAM: https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecdtg406.pdf
- Ch. 11 — European Commission. Commission Regulation (EU) No 640/2012 of 6 July 2012 amending Regulation (EC) No 440/2008, Annex, test method B.42: Skin sensitisation, local lymph node assay. https://legislation.gov.uk/eur/2012/640/data.pdf
- Ch. 11 — ISO. ISO 10993-10:2021 Biological evaluation of medical devices — Part 10: Tests for skin sensitization. Edition 4, November 2021. https://www.iso.org/standard/75279.html
- Ch. 11 — Jenvert R.-M., Larne O., Johansson A., Berglin M., Pedersen E., Johansson H. Evaluation of the applicability of GARDskin to predict skin sensitizers in extracts from medical device materials. Front Toxicol 6, 1320367 (2024). doi:10.3389/ftox.2024.1320367 (method developer's study: funded in its entirety by SenzaGen AB; four of six authors SenzaGen employees)
- Ch. 11 — ISO. ISO 10993-11:2017 Biological evaluation of medical devices — Part 11: Tests for systemic toxicity. Edition 3, September 2017. Clauses 1 to 4.11 hosted by iTeh Standards: https://cdn.standards.iteh.ai/samples/68426/b75ede6cc3e74fde94ff7cecea7d863e/ISO-10993-11-2017.pdf
- Ch. 11 — EMA, Committee for Medicinal Products for Human Use. Guideline on the limits of genotoxic impurities. CPMP/SWP/5199/02, EMEA/CHMP/QWP/251344/2006. Adopted 28 June 2006; valid until 31 January 2018, now superseded (a medicines guideline, not a device rule). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-limits-genotoxic-impurities_en.pdf
- Ch. 11 — ISO. ISO 10993-3:2026 Biological evaluation of medical devices — Part 3: Evaluation of genotoxicity, carcinogenicity, reproductive toxicity and developmental toxicity. Edition 4, August 2026. ISO catalogue page: https://www.iso.org/standard/88199.html
- Ch. 11 — ISO. ISO 10993-3:2014 Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity. Edition 3, October 2014; withdrawn. https://www.iso.org/standard/55614.html · DIN. Project WI 00206101, FprEN ISO 10993-3. https://www.din.de/en/getting-involved/standards-committees/nafuo/projects/wdc-proj:din21:374893244
- Ch. 11 — Gehring T., Akdogan B. ISO 10993-3:2026 key changes: driving the shift from testing to risk-based evaluation. Eurofins, last updated 6 October 2026 (secondary; company staff of a testing laboratory). https://www.eurofins.com/en/biopharma-services/medical-device-services/resources/articles/iso-10993-32026-key-changes-driving-the-shift-from-testing-to-risk-based-evaluation/
- Ch. 12 — ISO. ISO 10993-12:2021, Biological evaluation of medical devices — Part 12: Sample preparation and reference materials. 5th edition, January 2021, with Amendment 1:2025. Opening pages, in French, hosted by iTeh Standards: https://cdn.standards.iteh.ai/samples/75769/46c10488bde345babdf30d8c7a901e04/ISO-10993-12-2021.pdf. Catalogue record: https://www.iso.org/standard/75769.html (it dates the close of a systematic review 5 June 2026 and gives no outcome)
- Ch. 12 — Ma L. Applying the appropriate extraction conditions for biocompatibility testing. Nelson Labs, 12 March 2025. https://nelsonlabs.com/applying-the-appropriate-extraction-conditions-for-biocompatibility-testing (a testing laboratory's article, company author; cites ISO 10993-12, 5th edition, clause 10.3.1)
- Ch. 12 — Jansen T., Wallin R.F. A practical guide to ISO 10993-12: sample preparation and reference materials. Medical Device & Diagnostic Industry (MD&DI), 1 December 1998. https://www.mddionline.com/materials/a-practical-guide-to-iso-10993-12-sample-preparation-and-reference-materials (trade press; authors at NAMSA, a contract testing laboratory; describes the first edition of 1996, since superseded)
- Ch. 12 — Heise T. (MED Institute). The new ISO 10993-18 standard. Slides, Nelson Labs Open House, Leuven, 4 March 2020. https://www.nelsonlabs.com/wp-content/uploads/2020/03/The-New-ISO-10993-18-Standard_Ted-Heise.pdf (a consultant's slides summarizing the standard, hosted by a testing laboratory; a secondary account, written before Amendment 1:2022; the view that 1.5 µg a day is excessively conservative for long-term implants is the presenter's own)
- Ch. 12 — FDA CDRH. Biocompatibility Town Hall #2: Extractions for Conducting Chemical Analysis for Biocompatibility Assessment. Transcript (FDA staff presentation, not guidance). 23 September 2026. https://www.fda.gov/media/195197/download (a document separate from the town hall's slides, media/195196)
- Ch. 13 — Yun B.H., Herath A., Jin Y.R., Kim J., Belton K., Rufer E.S., Rivera Betancourt O. Designing a set of reference standards for non-targeted analysis of polymer additives extracted from medical devices. Journal of Exposure Science & Environmental Epidemiology 35(6), 943–955 (2025). doi:10.1038/s41370-025-00788-w (FDA authors; internal FDA funding only; authors declare no competing interests)
- Ch. 13 — Nelson Labs. Good identification practices in non-targeted screening. Slides, medical device workshop (26 April 2023). https://www.nelsonlabs.com/wp-content/uploads/2023/04/4.-Good-Identification-Practices-in-Non-Targeted-Screening-Ward-DAutry.pdf (a testing laboratory's statement of its own practice, not an ISO or FDA rule; identification levels cited to USP <1663>)
- Ch. 13 — ISO. ISO 10993-18:2020/Amd 1:2022, Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process. Amendment 1: Determination of the uncertainty factor. May 2022. Opening pages hosted by iTeh Standards: https://cdn.standards.iteh.ai/samples/82241/59486ccbf47c44d682f79ee42d97ff9d/ISO-10993-18-2020-Amd-1-2022.pdf
- Ch. 13 — Oktem B., Nahan K., Sussman E.M., Yun B.H., Patabandige M.W., Wickramasekara S. Considerations for uncertainty factor determination in medical device extractables analysis. Poster, FDA Science Forum 2021. https://www.fda.gov/science-research/fda-science-forum/considerations-uncertainty-factor-determination-medical-device-extractables-analysis (FDA authors; conference poster, not peer reviewed; initial data)
- Ch. 13 — FDA. ASCA 2024 presentations on extractables coverage and response factors (Pastarnak, Edwards Lifesciences; Christiaens, Nelson Labs; Zhang, Abbott; Rowland, RQM+). 6 November and 5 December 2024. https://fda.gov/media/184352/download (industry and laboratory slides hosted by FDA; each figure is its presenter's company's own)
- Ch. 13 — Environment Canada; Health Canada. Screening Assessment for the Challenge: Octamethylcyclotetrasiloxane (D4), CAS RN 556-67-2 (November 2008). https://www.canada.ca/content/dam/eccc/documents/pdf/batch2_556-67-2_en_v2.pdf
- Ch. 14 — Kennedy T. (W.L. Gore & Associates), Parker S. (SParker Toxicology Consulting), Hood A. (FDA CDRH). ISO 10993-17 MDCPSS Webinar Part 2. Society of Toxicology, Medical Device and Combination Product Specialty Section (24 January 2024). https://www.toxicology.org/groups/ss/MDCPSS/docs/_mtg-events/ISO-10993-17-MDCPSS-Webinar-Part-2.pdf (webinar slides citing the standard; one presenter FDA staff, one a device maker's staff and one a toxicology consultant)
- Ch. 14 — ISO. Biological evaluation of medical devices — Part 17: Toxicological risk assessment of medical device constituents. ISO 10993-17:2023, second edition (2023). Foreword and clauses 1 to 5.1.2 hosted by iTeh Standards: https://cdn.standards.iteh.ai/samples/75323/957608d0c3e149eab515c57213bee3d6/ISO-10993-17-2023.pdf
- Ch. 14 — US EPA. Integrated Risk Information System (IRIS) Chemical Assessment Summary: Di(2-ethylhexyl)phthalate (DEHP), CASRN 117-81-7. Reference dose last revised 31 January 1987; cancer assessment 7 September 1988. https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0014_summary.pdf
- Ch. 14 — Carpenter C.P., et al. Archives of Industrial Hygiene and Occupational Medicine 8, 219–226 (1953) (the principal study behind EPA's DEHP reference dose, as cited in EPA's IRIS summary)
- Ch. 14 — US EPA, Office of Chemical Safety and Pollution Prevention. Draft Human Health Hazard Assessment for Octamethylcyclotetrasiloxane (D4). Technical support document for the Draft Risk Evaluation, EPA-740-D-25-030 (September 2025). https://www.epa.gov/system/files/documents/2025-09/19.-d4.-draft-human-health-hazard-assessment.-public-release.-sept-2025.pdf (public release draft; EPA's Science Advisory Committee on Chemicals reviewed it at a public meeting on 2 to 5 December 2025, and the risk evaluation was not final as of 14 November 2026, per EPA's D4 risk-evaluation page, https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-evaluation-octamethylcyclotetrasiloxane-d4)
- Ch. 14 — WIL Research. Two-generation inhalation reproductive toxicity study of octamethylcyclotetrasiloxane in rats (2001) (the principal study of EPA's draft assessment, as cited there; WIL Research is a contract laboratory)
- Ch. 14 — Gruber S. ISO 10993-17: what the standard has changed and now requires from manufacturers. Johner Institute, undated article published after the autumn of 2023. https://johner-institute.com/articles/biocompatibility/iso-10993-17-what-the-standard-has-changed-and-now-requires-from-manufacturers/ (consultancy that sells services)
- Ch. 14 — Efor Group. ISO 10993-17:2023 Explained: Toxicological Risk (25 September 2023, no author named). https://efor-group.com/?p=6211 (consultancy that sells services)
- Ch. 14 — Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment (COT). COT Statement on Dietary Exposure to Phthalates — Data from the Total Diet Study. Statement 2011/04 (May 2011). https://cot.food.gov.uk/sites/default/files/cot/cotstatementphthalates201104.pdf (prints the basis of EFSA's 2005 value for DEHP)
- Ch. 14 — EFSA CEP Panel. Update of the risk assessment of DBP, BBP, DEHP, DINP and DIDP for use in food contact materials. EFSA Journal, publication 5838 (2019). https://efsa.europa.eu/en/efsajournal/pub/5838
- Ch. 14 — FDA. Recognized Consensus Standards: Medical Devices. ISO 10993-17 Second edition 2023-09, recognition number 2-303, entered 18 December 2023, partial. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.cfm?standard__identification_no=44811
- Ch. 15 — FDA CDRH. CHemical RISk calculator (CHRIS) — Color additives. README, undated; on 13 November 2026 it described the calculator as a tool under development. https://caas-cdrh-app1-ext-awse.fda.gov/color2_module/README.html (FDA tool documentation, not guidance)
- Ch. 15 — More S. (MCRA LLC, Associate Director, Toxicology). Updates to Conducting Toxicological Risk Assessment of Medical Device Constituents. Orthopedic Design & Technology, Orthopedic Insights column, issue of 1 November 2023. https://www.odtmag.com/issues/2023-11-01/view_columns/updates-to-conducting-toxicological-risk-assessment-of-medical-device-constituents/ (consultancy author in a trade magazine)
- Ch. 15 — FDA CDRH. Biocompatibility Town Hall #3: Toxicological Risk Assessment Approaches for Addressing Biocompatibility Endpoints (7 October 2026). Transcript: https://www.fda.gov/media/195695/download; slides: https://www.fda.gov/media/195696/download (FDA staff presentation and spoken answers, not guidance; the margin-of-safety outcomes are on slide 28)
- Ch. 15 — NAMSA. How the Updated ISO 10993-17:2023 Could Change Toxicological Risk Assessment. Web article, undated, no author shown. https://namsa.com/?p=30852 (contract research organization that sells testing)
- Ch. 15 — Garry M., Arnold M. ISO Updates Standard for Medical Device Toxicological Risk Assessments. Exponent (20 September 2023). https://www.exponent.com/article/iso-updates-standard-medical-device-toxicological-risk-assessments (consultancy)
- Ch. 15 — Zhang K., Wong J.W., Begley T.H., Hayward D.G., Limm W. (FDA). Determination of siloxanes in silicone products and potential migration to milk, formula and liquid simulants. Food Additives & Contaminants Part A 29(8), 1311–1321 (2012). doi:10.1080/19440049.2012.684891 (FDA-authored measurement in food-contact silicone products)
- Ch. 16 — ISO. ISO/TS 21726:2019 Biological evaluation of medical devices — Application of the threshold of toxicological concern (TTC) for assessing biocompatibility of medical device constituents. 2019. Opening pages to clause 4.1 hosted by iTeh Standards: https://cdn.standards.iteh.ai/samples/71514/55b55b9c79a94b11bb2c1d5a783eccd4/ISO-TS-21726-2019.pdf
- Ch. 16 — Builee T., Kennedy T.A., Levelut V., Hahn M.A., Bond S., Peterson M.K., Hsia F.K., Stornetta A., Erickson K.J., Ehman K.D., Prabhakar B., Bagley B.D., Parker S.P., and four others. Characterization of medical device constituents and development of duration-based non-cancer threshold of toxicological concern values. Front Toxicol 7, 1600127 (2025). doi:10.3389/ftox.2025.1600127 (most authors staff of device makers and testing laboratories; publication fees paid by Gradient, NAMSA, Nelson Labs, Solventum, WuXi AppTec and W.L. Gore; the duration-based values are a proposal, not adopted in a standard)
- Ch. 16 — Munro I.C. and colleagues (1996). The Cramer-class thresholds of toxicological concern (values as reproduced in Builee et al. 2025, Table 4, and in Efor Group 2025 and EFSA's 2018 consultation draft)
- Ch. 16 — ICH; FDA (CDER, CBER). M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. Guidance for Industry (July 2023; ICH Step 4, April 2023). https://fda.gov/media/170461/download (contains nonbinding recommendations)
- Ch. 16 — Efor Group. Thresholds of Toxicological Concern (TTC). Technical article (6 November 2025, no author named). https://efor-group.com/en/thresholds-of-toxicological-concern-ttc/ (consultancy that sells services; it cites Kroes and colleagues, 2004, for the 0.15 µg a day for compounds with genotoxic alerts)
- Ch. 16 — iTeh Standards. Catalogue record for ISO/TS 21726:2019, reproducing ISO's record and abstract (viewed 13 November 2026: stage 90.92, to be revised, from 10 October 2025). https://standards.iteh.ai/catalog/standards/iso/ebc3c45e-a517-46d8-850a-13ba1b965b7a/iso-ts-21726-2019 (a standards seller's page)
- Ch. 16 — FDA. Recognized Consensus Standards: Medical Devices. ISO TS 21726 First edition 2019-02, recognition number 2-268, entered 15 July 2019, complete standard. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/detail.cfm?standard__identification_no=39076
- Ch. 16 — EFSA Scientific Committee. Guidance on the use of the Threshold of Toxicological Concern approach in food safety assessment. Draft for public consultation, 2018 (the document carries no date). https://www.efsa.europa.eu/sites/default/files/consultation/consultation/181112-d.pdf (superseded by the guidance adopted in 2019, listed below)
- Ch. 16 — EFSA Scientific Committee. Guidance on the use of the Threshold of Toxicological Concern approach in food safety assessment. EFSA Journal. 2019;17(6):5708. Adopted 24 April 2019; published 6 June 2019. https://www.efsa.europa.eu/en/efsajournal/pub/5708
- Ch. 16 — EFSA. Threshold of toxicological concern. Topic page. https://www.efsa.europa.eu/en/topics/topic/thresholdtoxicologicalconcern
- Ch. 16 — Efor Group. Focus on AET and TSL. Technical article (17 April 2024, no author named). https://efor-group.com/en/focus-on-aet-and-tsl/ (consultancy that sells services)
- Ch. 17 — PMDA. Standards-information page on ISO 10993-18 Ed. 2 (January 2020, ISO/TC 194/WG 14). https://www.std.pmda.go.jp/stdDB/Data_en/InfData/Infetc/kikaku_info_iso10993-18_ed2.pdf (a regulator's summary page; no formula)
- Ch. 17 — De Roeck A. ISO 10993-18: introduction to E&L testing for medical devices. Slides, Nelson Labs medical device workshop (26 April 2023). https://www.nelsonlabs.com/wp-content/uploads/2023/04/3.-ISO-10993-18-Intro-to-EL-testing-for-Medical-devices-Ans-De-Roeck.pdf (a testing laboratory's workshop slides, with a worked AET example)
- Ch. 17 — FDA. CDRH Proposed Guidances for Fiscal Year 2027 (posted 1 October 2026). https://www.fda.gov/media/195054/download?attachment
- Ch. 18 — ISO. ISO 10993-5:2009 Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity. Third edition. Cover to the end of the Introduction on the ANSI Webstore, a reseller: https://webstore.ansi.org/preview-pages/ISO/preview_ISO+10993-5-2009.pdf
- Ch. 18 — Institute for Standardization of Serbia (ISO member body). Project records ISO/PWI 10993-5, iso:proj:85211 (abandoned 16 June 2025) and iso:proj:93386 (received 19 November 2025). https://iss.rs/en/project/show/iso:proj:85211 ; https://iss.rs/en/project/show/iso:proj:93386 (national member body's mirror of ISO project data)
- Ch. 18 — Eurofins Medical Device Services. Elution test (cytotoxicity). Undated service page, accessed 13 November 2026. https://www.eurofins.com/en-de/biopharma-services/medical-device-services/biocompatibility-testing/cytotoxicity/elution-test/ (contract laboratory)
- Ch. 18 — Nelson Labs. Cytotoxicity testing. Undated service page, accessed 13 November 2026. https://www.nelsonlabs.com/testing/cytotoxicity/ (contract laboratory)
- Ch. 18 — Gruber S., Nickel A. Toxic or not toxic? The specifications of the standard ISO 10993-5 are not explicit enough to yield comparable results in the cytotoxicity assessment of an identical medical device. Front Med Technol 5, 1195529 (2023). doi:10.3389/fmedt.2023.1195529 (interlaboratory comparison, 52 laboratories in 18 countries; authors of Johner Institut GmbH, a regulatory consultancy; no external funding)
- Ch. 18 — Gruber S. Cytotoxicity testing according to EN ISO 10993-5: avoiding pitfalls when choosing a laboratory. Johner Institute blog, 31 March 2022, updated 17 December 2025. https://blog.johner-institute.com/regulatory-affairs/cytotoxicity-testing/ (consultancy blog; reproduces the standard's limit and grade table, not the clause)
- Ch. 18 — Vanderkelen L. A stepwise approach to deal with in vitro cytotoxicity failures. Nelson Labs, 21 March 2022. https://nelsonlabs.com/a-stepwise-approach-to-deal-with-in-vitro-cytotoxicity-failures (contract laboratory staff)
- Ch. 18 — Rääget H., Turley A.P., Fish T.J., Franson J., Rollins T.S., Campbell S., Jorgensen M.R. Medical device industry approaches for addressing sources of failing cytotoxicity scores. Biomed Instrum Technol 55(2), 69–84 (2021). doi:10.2345/0899-8205-55.2.69 (all authors Nelson Laboratories staff)
- Ch. 18 — De Jong W.H., Hoffmann S., Lee M., Kandárová H., et al. (37 authors; last Coleman K.P.). Round robin study to evaluate the reconstructed human epidermis (RhE) model as an in vitro skin irritation test for detection of irritant activity in medical device extracts. Toxicol In Vitro 50, 439–449 (2018). doi:10.1016/j.tiv.2018.01.001 (authors include staff of MatTek and EPISKIN, the models' makers, of contract laboratories, of device makers and of FDA CDRH)
- Ch. 18 — De Jong W.H., Carraway J.W., Liu C., et al. (last Coleman K.P., Medtronic). The suitability of reconstructed human epidermis models for medical device irritation assessment: a comparison of in vitro and in vivo testing results. Toxicol In Vitro 69, 104995 (2020). doi:10.1016/j.tiv.2020.104995 (authors from NAMSA, Nelson Labs, Medtronic, China NMPA and Shandong Institute)
- Ch. 18 — ISO. ISO/TS 11796:2023 Biological evaluation of medical devices — Requirements for interlaboratory studies to demonstrate the applicability of validated in vitro methods to assess the skin sensitization of medical devices. Edition 1, July 2023. Catalogue page hosted by iTeh Standards: https://iteh.es/catalog/standards/iso/6faf26c6-c5ec-40db-9930-8af8a97697e6/iso-ts-11796-2023
- Ch. 18 — Tenhunen E. (Measurlabs). Genotoxicity testing of medical devices under the revised ISO 10993-3 standard. 10 November 2026. https://measurlabs.com/blog/genotoxicity-testing-iso-10993-3/ (test laboratory blog)
- Ch. 18 — ISO. ISO 10993-2:2022 Biological evaluation of medical devices — Part 2: Animal welfare requirements. Edition 3, November 2022. Cover, foreword, introduction and contents on the ANSI Webstore, a reseller: https://webstore.ansi.org/preview-pages/ISO/preview_ISO+10993-2-2022.pdf
- Ch. 18 — FDA CDRH. Webinar transcript: final guidance "Use of International Standard ISO 10993-1". 12 October 2023. https://fda.gov/media/173290/download
- Ch. 18 — FDA. FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs. Press announcement, 10 April 2025. https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs
- Ch. 18 — FDA. Roadmap to Reducing Animal Testing in Preclinical Safety Studies. Undated (linked from the release of 10 April 2025). https://www.fda.gov/media/186092/download?attachment
- Ch. 18 — Berman J.R., Seeley A.Z. (Morgan Lewis). Innovation at the FDA: efforts to decrease animal testing and usher in new technologies. 24 March 2026. https://www.morganlewis.com/pubs/2026/03/innovation-at-the-fda-efforts-to-decrease-animal-testing-and-usher-in-new-technologies (law-firm commentary)
- Ch. 19 — FDA. Notice of modifications to the list of recognized standards, recognition list number 062. Federal Register, 24 June 2024, document 2024-13777. https://www.govinfo.gov/content/pkg/FR-2024-06-24/html/2024-13777.htm (states the modifications applicable 24 June 2024; lists recognitions 1-173 to 1-175 as replacing 1-134 to 1-136)
- Ch. 19 — FDA. Recognized Consensus Standards: Medical Devices. ISO 18562-1 Second edition 2024-03, recognition number 1-173 (partial: clauses 7.2 b) 1) and 7.3 b) 1) not recognized), entered 29 May 2024. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.cfm?standard__identification_no=45207 (accessed 13 November 2026)
- Ch. 19 — FDA. Recognized Consensus Standards: Medical Devices. ISO 18562-3 Second Edition 2024-03, recognition number 1-175, entered 29 May 2024. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/detail.cfm?standard__identification_no=45211 (accessed 13 November 2026)
- Ch. 19 — FDA. Recognized Consensus Standards, record 45214: ISO 80601-2-74 (second edition 2021-07), recognition number 1-177, whose relevant standards include ISO 18562-1 through -4, second edition 2024-03. Entered 29 May 2024. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/detail.cfm?standard__identification_no=45214
- Ch. 19 — Saavalainen J. (Measurlabs). Biological evaluation of breathing gas pathways in accordance with ISO 18562. Blog article, 4 March 2026. https://measurlabs.com/blog/iso-18562-biocompatibility-of-breathing-gas-pathways/ (test laboratory that sells ISO 18562 testing; company staff; describes the 2024 editions)
- Ch. 19 — Keller B. (IMT Information Management Technology AG). Biocompatibility evaluation of breathing gas pathways in healthcare applications. Expert blog, undated (page metadata modified 26 October 2022). https://www.imt.ch/en/expert-blog-detail/biocompatability-breathing-gas-pathways-en (device development company; the author its head of regulatory affairs and quality management; edition of the standard not stated)
- Ch. 19 — Turner M. (Medical Engineering Technologies). Biocompatibility of medicinal product–medical device combinations for airway delivery. ONdrugDelivery 119, 42–45 (April–May 2021). https://ondrugdelivery.com/biocompatibility-of-medicinal-product-medical-device-combinations-for-airway-delivery/ (trade-journal article by a test laboratory that sells breathing-component testing; describes the 2017 editions)
- Ch. 19 — Aichner V.S. (Eurofins BioPharma Product Testing Munich GmbH). How to sample and to analyse VOCs of respiratory medical devices according to the new ISO 18562-3. Pharm Ind 80(10), 1423–1427 (2018). https://cdnmedia.eurofins.com/eurofins-germany/media/2848741/pi8010_1561_aichner_10-18_05nov18.pdf (methods article by test-laboratory staff; the company sells the testing; describes the 2017 editions)
- Ch. 19 — ISO. ISO 18562-1:2024 Biocompatibility evaluation of breathing gas pathways in healthcare applications — Part 1: Evaluation and testing within a risk management process. Second edition, March 2024. Cover to p. vi on the ANSI Webstore, a reseller: https://webstore.ansi.org/preview-pages/ISO/preview_ISO+18562-1-2024.pdf
- Ch. 20 — FDA. FDA Activities Related to Recalled Philips Ventilators, BiPAP Machines, and CPAP Machines. Web page, content current as of 20 November 2024. https://www.fda.gov/medical-devices/recalled-philips-ventilators-bipap-machines-and-cpap-machines/fda-activities-related-recalled-philips-ventilators-bipap-machines-and-cpap-machines
- Ch. 20 — FDA. openFDA device recall records, recall events 88058 and 88071 (products Z-1956-2021 to Z-1958-2021 and Z-1972-2021 to Z-1974-2021). Accessed 13 November 2026. https://api.fda.gov/device/recall.json?search=res_event_number:"88058"+res_event_number:"88071"&limit=20 (openFDA states that its data are not validated)
- Ch. 20 — Philips (company announcement posted by FDA). Philips Issues a Recall Notification to Mitigate Potential Health Risks Related to the Sound Abatement Foam Component in Certain Sleep and Respiratory Care Devices. 14 June 2021. https://fda.gov/safety/recalls-market-withdrawals-safety-alerts/philips-issues-recall-notification-mitigate-potential-health-risks-related-sound-abatement-foam (manufacturer; FDA posts it as a public service and does not endorse the company)
- Ch. 20 — Philips. Ozone cleaner information. Business update, 8 February 2022. https://www.usa.philips.com/sleep-respiratory-care/news/business-updates/ozone-cleaner-information (manufacturer; cites FDA's safety communication of 27 February 2020 on ozone and UV light)
- Ch. 20 — Philips. Philips provides update on completed set of test results for CPAP/BiPAP sleep therapy devices. Press release, 16 May 2023. https://www.philips.fi/about/news-and-insights/press-release/philips-provides-update-on-completed-set-of-test-results-for-cpap-bipap-sleep-therapy-devices (manufacturer)
- Ch. 20 — U.S. Department of Justice, Office of Public Affairs. Court Enjoins Philips Respironics from Manufacturing and Distributing Adulterated and Misbranded Sleep and Respiratory Devices at or from Three Pennsylvania Facilities. Press release 24-416, 9 April 2024. https://www.justice.gov/opa/pr/court-enjoins-philips-respironics-manufacturing-and-distributing-adulterated-and-misbranded
- Ch. 20 — FDA. Federal Court Enters Consent Decree Against Philips Respironics Following Recall of Certain Sleep Therapy Machines. Press announcement, 9 April 2024. https://www.fda.gov/news-events/press-announcements/federal-court-enters-consent-decree-against-philips-respironics-following-recall-certain-sleep
- Ch. 20 — FDA CDRH. CDRH Provides Update on Philips June 2021 Recall and Maintains Recommendations Related to Potential Health Risks of PE-PUR Foam. 5 October 2023. https://www.fda.gov/medical-devices/medical-devices-news-and-events/cdrh-provides-update-philips-june-2021-recall-and-maintains-recommendations-related-potential-health
- Ch. 20 — FDA. Foam Testing Summary for Recalled Philips Ventilators, BiPAP Machines, and CPAP Machines. Web page, content current as of 15 August 2024. https://www.fda.gov/medical-devices/recalled-philips-ventilators-bipap-machines-and-cpap-machines/foam-testing-summary-recalled-philips-ventilators-bipap-machines-and-cpap-machines
- Ch. 20 — Philips. Respironics FAQ (June 14, 2021 recall notification / field safety notice), as of 3 November 2026. https://www.philips.com/c-dam/assets/corporate/global/investor/20261103_Respironics_FAQ.pdf (manufacturer; investor relations)
- Ch. 21 — Wallin R.F., Upman P.J. A practical guide to ISO 10993: Part 1, introduction to the standards. Medical Device & Diagnostic Industry (MD&DI), January 1998. https://www.mddionline.com/regulatory-quality/a-practical-guide-to-iso-10993-part-1-151-introduction-to-the-standards (trade press; authors at NAMSA, a contract testing laboratory)
- Ch. 21 — Wallin R.F. Improving biocompatibility standards for the global market. Medical Device & Diagnostic Industry (MD&DI), December 1996. https://www.mddionline.com/regulatory-quality/improving-biocompatibility-standards-for-the-global-market (trade press; author president of NAMSA, a contract testing laboratory)
- Ch. 21 — Genorma. ISO 10993-1:1997 (catalogue record). https://genorma.com/en/standards/iso-10993-1-1997 (standards seller's record; edition dates and withdrawal)
- Ch. 21 — Austrian Standards. ISO 10993-1:2003 (catalogue page, with the ISO abstract and edition timeline). https://austrian-standards.at/en/shop/iso-10993-1-2003-2003-07-28~p1394815 (national standards body's shop)
- Ch. 21 — Austrian Standards. ISO 10993-1:2009 (catalogue page, with the ISO abstract and edition timeline). https://austrian-standards.at/en/shop/iso-10993-1-2009-2009-10-13~p1765023 (national standards body's shop)
- Ch. 21 — FDA. Recognized Consensus Standards: ISO 10993-1 Sixth edition 2025-11, recognition number 2-313 (partial; clause 6.9 and the phrase "consumer products" in clause 6.5.11.3 not recognized). Date of entry 25 May 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfstandards/detail.cfm?standard__identification_no=47116
- Ch. 21 — Chiara A. (Complife). FDA partially recognizes ISO 10993-1:2025: what changes for biocompatibility. 12 June 2026. https://www.complifegroup.com/2026/06/12/what-changes-for-biocompatibility/ (testing laboratory's note, company; its link of clause 6.5.11.3 to Attachment G is the laboratory's inference)
- Ch. 22 — FDA. Quality Management System Regulation (QMSR). Web page. Content current as of 2 February 2026. https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
- Ch. 22 — ISO. ISO 14971:2019 Medical devices: Application of risk management to medical devices. Edition 3, December 2019; reviewed and confirmed 2025. Catalogue page. https://www.iso.org/standard/72704.html
- Ch. 22 — Tartal J. Risk Basics for Medical Devices. FDA CDRH training slides (training material, not guidance; reproduce the ISO 14971:2019 terms and the chain). Undated. https://fda.gov/media/163912/download
- Ch. 22 — TÜV NORD. Revision of ISO 10993-1: why the 2025 update matters for MDR alignment. Web article. 10 December 2025. https://www.tuev-nord.de/en/knowledge/standards-in-focus/revision-of-iso-10993-1-why-the-2025-update-matters-for-mdr-alignment/ (EU notified body; secondary account of the standard)
- Ch. 22 — FDA CDRH. QMSR training material on risk management. https://www.fda.gov/media/189040/download (training material, not guidance)
- Ch. 23 — Chiou A. MDSAP audit approach: enhancing supplier selection in purchasing. DQS blog. 13 September 2024. https://dqsglobal.com/intl/learn/blog/mdsap-audit-approach-enhancing-supplier-selection-in-purchasing (auditing organization's blog; secondary account of ISO 13485 clause 7.4)
- Ch. 23 — Agarwal N. QMSR Tip #2: Ensure product quality and patient safety with risk-based supplier agreements. Let's Talk Risk! (Substack newsletter). 11 September 2024. https://naveenagarwalphd.substack.com/p/qmsr-tip-2-ensure-product-quality-with-supplier-agreements (individual consultant; secondary; written before the QMSR took effect)
- Ch. 23 — FDA. Medical Devices; Quality System Regulation Amendments. Final rule. 89 FR 7496. 2 February 2024 (effective 2 February 2026). https://www.federalregister.gov/documents/2024/02/02/2024-01709/medical-devices-quality-system-regulation-amendments
- Ch. 23 — FDA. Medical Device Recalls database. Recall Z-0022-2022, OPTETRAK Comprehensive Knee System, Exactech, Inc. Class 2. Posted 4 October 2021. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/res.cfm?id=189261 (one record of a larger recall event)
- Ch. 23 — FDA. openFDA device recall endpoint: counts by root cause, for all records and for records whose reason contains "biocompatibility". Accessed 13 November 2026. https://api.fda.gov/device/recall.json?count=root_cause_description.exact ; https://api.fda.gov/device/recall.json?search=reason_for_recall:biocompatibility&count=root_cause_description.exact (live, unvalidated data; counts are product records)
- Ch. 23 — United States v. Philips RS North America LLC et al. Consent Decree of Permanent Injunction. No. 2:24-cv-00505-RJC (W.D. Pa.), Doc. 16. 9 April 2024. https://www.justice.gov/opa/media/1347246/dl?inline
- Ch. 25 — Covestro AG. Covestro and XRG commence strategic partnership: transaction successfully closed. Investor news, 10 December 2025. https://www.covestro.com/investors/news/covestro-and-xrg-commence-strategic-partnership-transaction-successfully-closed/ (the company's own announcement; XRG's stake after closing not stated)
- Ch. 25 — Elkem ASA. Elkem has sold majority of Silicones division to Bluestar. Transaction page, undated (after 30 April 2026). https://www.elkem.com/transaction/ (the company's own statement; announced 13 February 2026, completed 30 April 2026)
- Ch. 25 — Elkem. Elkem Silicones becomes Bluestar Silicones. News page, undated (after 30 April 2026). https://www.elkem.com/about-elkem/corporate-structure/elkem-silicones/about-elkem-silicones/silicones-news/elkem-silicones-becomes-bluestar-silicones/ (the company's own statement)
- Ch. 25 — Trinseo PLC. Trinseo takes next step to implement restructuring support agreement and strengthen financial foundation. Press release, 26 May 2026. https://investor.trinseo.com/home/news/news-details/2026/Trinseo-Takes-Next-Step-to-Implement-Restructuring-Support-Agreement-and-Strengthen-Financial-Foundation/default.aspx (the company's own statement)
- Ch. 25 — Trinseo PLC. Trinseo reports second quarter 2026 financial results. Press release, 6 August 2026. https://investor.trinseo.com/home/news/news-details/2026/Trinseo-Reports-Second-Quarter-2026-Financial-Results/default.aspx (the company's own statement)
- Ch. 25 — Trinseo PLC. Form 10-Q, quarter ended 30 September 2026. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/0001519061/000110465926124268/tse-20260930x10q.htm (the company's filing)
- Ch. 25 — DuPont de Nemours, Inc. DuPont launches Liveo C6-8XX liquid silicone rubber series for healthcare applications. Press release, Wilmington, Del., 3 February 2026. https://www.dupont.com/news/dupont-launches-liveo-c6-8xx-liquid-silicone-rubber-series-for-healthcare-applications.html (the company's own statements)
- Ch. 25 — MDO Staff. Lubrizol launches Tolerathane TPU for implants. Medical Design and Outsourcing, 11 February 2026. https://www.medicaldesignandoutsourcing.com/lubrizol-launches-tolerathane-tpu-implants/ (trade press reporting the company's release; the claim is Lubrizol's)
- Ch. 25 — NAMSA. NAMSA Completes Acquisition of WuXi AppTec US Medical Device Testing Business. Press release, PR Newswire via BioSpace, 3 March 2025. https://www.biospace.com/press-releases/namsa-completes-acquisition-of-wuxi-apptec-us-medical-device-testing-business (the company's own release; completion 28 February 2025; names no sites)
- Ch. 25 — Fierce Biotech. WuXi AppTec sells US medical device testing business to NAMSA. Undated. https://www.fiercebiotech.com/medtech/wuxi-apptec-sells-us-medical-device-testing-business-namsa (trade press; names the sites in Atlanta and St. Paul)
- Ch. 25 — Debbarma S. NAMSA acquires Labcorp's medical device testing assets. Medical Device Developments, 9 January 2026. https://www.medicaldevice-developments.com/news/namsa-acquires-labcorps-medical-device-testing-assets/ (trade press; the acquisition count is the company's; closing date not stated)
- Ch. 25 — ARCHIMED. Partnering with existing owners and management, ARCHIMED acquires majority interest in NAMSA, the world leader in medical device testing. 1 September 2020. https://www.archimed.group/news/partnering-with-existing-owners-and-management-archimed-acquires-majority-interest-in-namsa-the-world-leader-in-medical-device-testing/ (the owner's own statement; its descriptions of NAMSA are the owner's)
- Ch. 25 — Sotera Health Company. Form 10-Q, quarter ended 30 June 2026. SEC EDGAR, filed 6 August 2026. https://www.sec.gov/Archives/edgar/data/1822479/000182247926000047/shc-20260630.htm (the company's filing)
- Ch. 25 — FDA. Accreditation Scheme for Conformity Assessment (ASCA). Web page, content current as of 28 January 2026. https://www.fda.gov/medical-devices/division-standards-and-conformity-assessment/accreditation-scheme-conformity-assessment-asca
- Ch. 25 — FDA (CDRH, CBER). Biocompatibility Testing of Medical Devices: Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program. Guidance, 25 September 2020 (final; its page states that the pilot became a permanent program on 19 September 2023 and, as accessed on 13 November 2026, that the guidance is under revision). https://www.fda.gov/media/142388/download
- Ch. 25 — Sandhya C.G., Balram S. Internationally accredited testing services for medical devices, biomaterials and IVDs. SCTIMST, 31 July 2023. https://omsth.sctimst.ac.in/omsth/article/view/17 (the institute's own article, by its staff)
- Ch. 25 — Sandhya C.G. SCTIMST: your partner for testing and biological evaluation of medical devices and biomaterials. Advertising feature, 31 December 2023. https://omsth.sctimst.ac.in/omsth/article/view/29 (the institute's own promotional article, by its staff)
- Ch. 25 — Central Drugs Standard Control Organization. Medical Device & Diagnostics: notices and lists of medical device testing laboratories registered under the Medical Devices Rules 2017. Web page, accessed 13 November 2026. https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/Medical-Device-Diagnostics/
- Ch. 25 — NABL (National Accreditation Board for Testing and Calibration Laboratories). Introduction. Web page. Accessed 14 November 2026. https://nabl-india.org/introduction/
- Ch. 25 — 21 CFR Part 58, Good Laboratory Practice for Nonclinical Laboratory Studies, §§ 58.1 and 58.3. eCFR, up to date as of 22 October 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-58/subpart-A
- Ch. 25 — ISO. ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories. 3rd edition, November 2017; confirmed 2023. https://www.iso.org/standard/66912.html
- Ch. 26 — FDA. Modifications to the List of Recognized Standards, Recognition List Number: 066. Federal Register 91(162):54715–54721. FR Doc. 2026-17229. 24 August 2026. https://www.govinfo.gov/content/pkg/FR-2026-08-24/html/2026-17229.htm
- Ch. 26 — eCFR. 21 CFR 860.3 Definitions. Up to date as of 22 October 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-860/subpart-A/section-860.3
- Ch. 26 — eCFR. 21 CFR 820.10 Requirements for a quality management system. Up to date as of 23 October 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-820/subpart-A/section-820.10
- Ch. 26 — FDA. Classify Your Medical Device. Web page. Content current as of 26 August 2026. https://fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device
- Ch. 26 — FDA. De Novo database: DEN150011, Sonablate 450. Granted 9 October 2015 (FDA's description of the route: "low to moderate risk"). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN150011
- Ch. 26 — FDA. Color Additives for Medical Devices. Biocompatibility Assessment Resource Center (web resource). Content current as of 10 August 2022. https://www.fda.gov/medical-devices/biocompatibility-assessment-resource-center/color-additives-medical-devices
- Ch. 26 — FDA. openFDA device classification records, product codes BZD (Ventilator, Non-Continuous (Respirator), class 2) and BTT (Humidifier, Respiratory Gas, class 2). Accessed 13 November 2026 (openFDA states its data are unvalidated). https://api.fda.gov/device/classification.json?search=product_code:BZD+product_code:BTT+product_code:BYD&limit=5
- Ch. 26 — FDA. Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices. Guidance for industry and FDA staff. 14 September 2018. Docket FDA-2014-D-0456. https://www.fda.gov/media/71983/download
- Ch. 27 — European Parliament and Council. Regulation (EU) 2017/745 of 5 April 2017 on medical devices (MDR), Annex I, Chapter II, section 10 (points 10.1 to 10.4.5), text as adopted. legislation.gov.uk. https://www.legislation.gov.uk/eur/2017/745/annex/I/adopted/data.pdf
- Ch. 27 — iTeh Standards (a standards seller), reproducing CEN's data. EN ISO 10993-5:2009/A11:2025, catalogue page: revised European foreword and Annex ZA relating the standard to Regulation (EU) 2017/745 under mandate M/575. Published 4 March 2025. https://standards.iteh.ai/catalog/standards/cen/0c36fdb0-4ae8-42ed-b7c9-308d81653562/en-iso-10993-5-2009-a11-2025 (secondary)
- Ch. 27 — European Commission, DG GROW. Summary list of harmonised standards, Regulation (EU) 2017/745. Generated 17 June 2026 (informative; the Official Journal is the legal reference). https://webgate.ec.europa.eu/circabc-ewpp/d/d/workspace/SpacesStore/df35c144-be9d-490c-90e6-847cc9dbcc32/download, linked from https://single-market-economy.ec.europa.eu/single-market/goods/european-standards/harmonised-standards/medical-devices_en
- Ch. 27 — European Parliament and Council. Regulation (EU) 2017/745 of 5 April 2017 on medical devices (MDR), consolidated text of 1 January 2026 (02017R0745-20260101), Articles 2(42), 2(43) and 20, and Annex I, Chapter II, points 10.3 to 10.4.5 (point 10.4.3 as amended by Regulation (EU) 2025/2457). EUR-Lex. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02017R0745-20260101
- Ch. 28 — Ministry of Health and Family Welfare. Medical Devices Rules, 2017. G.S.R. 78(E), 31 January 2017, in force 1 January 2018, as amended to G.S.R. 777(E), 14 October 2022. CDSCO upload. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/m_device/mdr,%202017%20(1).pdf
- Ch. 28 — Central Drugs Standard Control Organization. Regulatory documents and license forms under MDR 2017 (summary). https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/medical-device/RegulatoryMDR-2017.pdf
- Ch. 28 — Central Drugs Standard Control Organization. Acts and Rules: Medical Devices Rules. Web page, accessed 13 November 2026. https://cdsco.gov.in/opencms/opencms/en/Acts-and-rules/Medical-Devices-Rules/ (lists the amending notifications by title and date; latest listed G.S.R. 409(E), 2 June 2023)
- Ch. 28 — Ministry of Health and Family Welfare. Guidance Document on Medical Devices: Essential Principles for safety and performance of medical devices. July 2017. https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/Essential_Principles_for_safety_47.pdf (the CDSCO copy is labeled a draft enclosure)
- Ch. 28 — Bureau of Indian Standards. Programme of work, Medical Equipment and Hospital Planning Department, committee MHD 19 (In-vitro Diagnostic Medical Devices and Biological Evaluation of Medical Devices). Generated on request, accessed 13 November 2026. https://www.services.bis.gov.in/php/BIS_2.0/bisconnect/pow_new/Pow/download_pow_pdf_dept_commtt/64/25
- Ch. 28 — Department of Science and Technology, National GLP Compliance Monitoring Authority. Certified Test Facilities with Test Items and Test Systems. 12 May 2026. https://dst.gov.in/sites/default/files/Certified%20Test%20Facilities%20withTest%20Items%20and%20Test%20Systems%201205026.pdf (counts not printed)
- Ch. 28 — National GLP Compliance Monitoring Authority. Application Form of NGCMA. GLP-102, Issue 08, 9 May 2022. https://dst.gov.in/sites/default/files/GLP-102_3.pdf
- Ch. 28 — Press Information Bureau, Ministry of Science and Technology. Release ID 1844717 (NGCMA). 25 July 2022. https://pib.gov.in/PressReleasePage.aspx?PRID=1844717
- Ch. 28 — Central Drugs Standard Control Organization (Drugs Controller General (India)). Classification of medical devices: merged device-wise lists, including Anaesthesiology (File No. 29/Misc/03/2020-DC(177)), Respiratory (File No. 29/Misc/03/2020-DC(197)) and Pediatrics and Neonatology (File No. 29/Misc./03/2020-DC (150)). https://www.cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/MDmergeclassification15oct25.pdf
Let's Talk